Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P33527 (
ABCC1
)
1,164
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Emerging evidence has validated the vital role of long non-coding RNA (lncRNA) in the chemoresistance of cancer treatment. In the present study, we investigate the function of lncRNA
NR2F1
-AS1 on oxaliplatin (OXA) resistance of hepatocellular carcinoma (HCC) and discover the underlying molecular mechanism. Results revealed that lncRNA
NR2F1
-AS1 was up-regulated in oxaliplatin-resistant HCC tissue and cells using microarray analysis and RT-PCR. Meanwhile,
ABCC1
protein was overexpressed in OXA-resistant HCC cells (Huh7/OXA and HepG2/OXA). In vitro,
NR2F1
-AS1 knockdown reduced the invasion, migration, drug-resistant gene (MDR1, MRP5, LRP1) and IC50 value in Huh7/OXA and HepG2/OXA cells. In vivo,
NR2F1
-AS1 knockdown decreased the tumour weight of HCC cells. Bioinformatics tools and luciferase reporter assay confirmed miR-363 targeted the 3'-UTR of
NR2F1
-AS1 and
ABCC1
mRNA, presenting that
NR2F1
-AS1 promoted
ABCC1
expression through endogenous sponging miR-363. In summary, results conclude that
NR2F1
-AS1 regulates HCC OXA resistance through targeting miR-363-
ABCC1
pathway, providing a vital theoretic mechanism and therapeutic target for HCC chemoresistance.
...
PMID:LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363. 2960 3